RDHL RedHill Biopharma Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1553846
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY33.2%
TTM net income YoY-28.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR117.3%
Net income 3-yr CAGR—
Margins
Gross margin42.4%
Operating margin-94.6%
Net margin-114.0%
FCF margin-76.0%
EBITDA margin—
Returns
ROE-859.7%
ROA-54.1%
ROIC (approx.)-99.4%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets95.1%
Debt / equity9.42x
Current ratio1.09x
Interest coverage-4.87x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-18.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.04M | $6.53M |
| Cost of revenue | $3.19M | $3.46M |
| Gross profit | $4.85M | $3.07M |
| R&D expense | $1.59M | $3.53M |
| SG&A expense | $9.57M | $16.22M |
| Operating income | -$14.61M | $12.63M |
| Interest expense | $2.06M | $9.61M |
| Net income | -$8.27M | $23.92M |
| EPS (basic) | 0.00 | 0.01 |
| EPS (diluted) | 0.00 | 0.01 |
| Balance sheet | ||
| Cash & equivalents | $4.62M | $5.57M |
| Receivables | $2.54M | $2.59M |
| Inventory | $3.65M | $4.39M |
| Current assets | $11.91M | $16.14M |
| PP&E, netmay include right-of-use assets (IFRS) | $135,000 | $193,000 |
| Intangibles | $5.55M | $5.58M |
| Total assets | $18.04M | $23.05M |
| Current liabilities | $22.22M | $19.98M |
| Total liabilities | $22.73M | $20.98M |
| Shareholders' equity | -$4.68M | $2.07M |
| Cash flow statement | ||
| Operating cash flow | -$9.37M | -$35.82M |
| Capital expenditure | $9,000 | $11,000 |
| Free cash flow | -$9.38M | -$35.83M |
| Investing cash flow | -$9,000 | $4,000 |
| Financing cash flow | $8.42M | $21.44M |
| Stock-based compensation | $665,000 | $1.65M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.